Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents

Medinger, Michael and Halter, Jörg and Heim, Dominik and Buser, Andreas and Gerull, Sabine and Lengerke, Claudia and Passweg, Jakob. (2016) Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents. Cancer genomics & proteomics, 13 (4). pp. 275-279.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/43894/

Downloads: Statistics Overview


Novel agents such as thalidomide, lenalidomide and bortezomib have in part anti-angiogenic properties. In this study, we examined gene expression of angiogenic molecules in patients with plasma cell myeloma (PCM).; We included 93 patients with PCM treated with novel agents (immunomodulatory drugs (IMiDs), bortezomib or a combination of both). The mRNA levels of angiogenic molecules were measured using the Human Angiogenesis RT2 Profiler PCR Array. The response evaluation was performed after three cycles.; Regarding all 93 patients, gene expression of 15 out of 84 genes tested (pre- and post-treatment and changes in levels pre-treatment/post-treatment) were significantly different in responders compared to non-responders. Responders had a lower expression of pro-angiogenic factors and increased expression of antiangiogenic factors.; In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.
Faculties and Departments:03 Faculty of Medicine
UniBasel Contributors:Medinger, Michael
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:International Institute of Anticancer Research
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:05 Jan 2017 09:06
Deposited On:05 Jan 2017 09:06

Repository Staff Only: item control page